Elite Pharmaceuticals, Inc. To Participate In Roth Capital’s 2006 New York Conference

NORTHVALE, N.J.--(BUSINESS WIRE)--Aug. 31, 2006--Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (AMEX: ELI), has been selected to participate in Roth Capital’s 2006 New York Conference focused on micro- and small-cap companies with market capitalizations below $500 million. Bernard Berk, Elite’s Chairman and Chief Executive Officer will discuss the Company’s two lead opioid products: ELI-216 ART(TM), the Company’s abuse-resistant oxycodone hydrochloride product and ELI-154, its once-daily oxycodone hydrochloride product.